A phase I/II study of PTK787 [vatalanib] in combination with trastuzumab in patients with newly diagnosed HER2 overexpressing locally recurrent or metastatic breast cancer: Hoosier Oncology Group Trial BRE04-80

Trial Profile

A phase I/II study of PTK787 [vatalanib] in combination with trastuzumab in patients with newly diagnosed HER2 overexpressing locally recurrent or metastatic breast cancer: Hoosier Oncology Group Trial BRE04-80

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2015

At a glance

  • Drugs Vatalanib (Primary) ; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Nov 2007 Patient numbers amended from 37 to 7
    • 01 Nov 2007 Status changed from in progress to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top